NCT02235272已完成3 期
A Multicenter, Randomized, Double-masked, Vehicle-controlled, Parallel Group Phase III Study of the Efficacy and Safety of a Single Sub-conjunctival Injection of XG-102 for the Reduction of Post-cataract Surgery Intraocular Inflammation
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Xigen SA
- 入组人数
- 339
- 主要终点
- Absence of anterior chamber cells for the 900µg XG-102 sub-conjunctival injection compared to vehicle
研究概览
简要总结
The purpose of this study is to evaluate the clinical efficacy and safety of XG-102 (900µg) compared to vehicle in the treatment of subjects with inflammation and pain following cataract surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have provided written informed consent, approved by the appropriate institutional review board;
- •Be greater than or equal to 18 years of age of either sex or any race;
- •Be planning to undergo unilateral cataract extraction via phacoemulsification and posterior chamber intraocular lens (PCIOL) implantation in the study eye;
- •Have a pin-hole visual acuity (VA) < 1.0 logarithm of the minimum angle of resolution (logMAR) in the operative eye and fellow eye as measured using an Early Treatment for Diabetic Retinopathy Study (ETDRS) chart at Visit 1;
- •(For females of childbearing potential) agree to have urine pregnancy testing performed at Visit 1 (must be negative) and at exit visit; must not be lactating; and must agree to use a medically acceptable form of birth control1 throughout the study duration. Women of childbearing potential include all females who have experienced menarche and have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months) or have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy).
排除标准
- •Have a known sensitivity or allergy to the class of medication of the active ingredient in the study medication or any of the study medication's components;
- •Have any intraocular inflammation (e.g., white blood cells or flare) present in the study eye at the Visit 1slit lamp examination;
- •Have a score greater than "0" on the Ocular Pain Assessment at Visit 1 or 2 in the study eye;
- •Have an immunosuppressive or an autoimmune disease that in the opinion of the Investigator could affect intraocular inflammation or the normal healing process of the eye;
- •Have active or chronic/recurrent ocular or systemic disease that is uncontrolled and will likely affect wound healing;
- •Currently have suspected or known malignancy or be currently receiving antineoplastic therapy;
- •Be a female who is currently pregnant, planning a pregnancy, lactating, not using a medically acceptable form of birth control throughout the study duration, or have a positive urine pregnancy test at Visit 1;
- •Use anti-inflammatory agents, analgesics/pain relievers (including opioids, narcotics and other pain medications) or immunomodulating agents, systemically, or in either eye, and/or use medications for benign prostatic hyperplasia (BPH), from the washout period through the duration of the study
研究组 & 干预措施
XG-102
Experimental
干预措施: XG-102 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Absence of anterior chamber cells for the 900µg XG-102 sub-conjunctival injection compared to vehicle
时间窗: Day 15
Absence of pain for the 900µg XG-102 compared to vehicle
时间窗: Day2
次要结局
- Use of rescue medication(up to Day 85)
研究者
相似试验
已完成
3 期
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and PainInflammationPainCataractNCT02508337Xigen SA309
已完成
2 期
Study of NGX-1998 for the Treatment of Postherpetic NeuralgiaPainPostherpetic NeuralgiaNCT01228838NeurogesX183
已完成
2 期
Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702Rheumatoid ArthritisNCT00205478Vertex Pharmaceuticals Incorporated300
已完成
2 期
Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux EsophagitisReflux EsophagitisNCT04531475Jiangsu Sinorda Biomedicine Co., Ltd90
已完成
2 期
A Phase II Study to Treat Advanced Malignant GliomaAdvanced Malignant GliomaNCT00427440Amgen61